MEET US AT THE 10TH INTERNATIONAL PEPTIDE SYMPOSIUM
|Product Name||Active Ingredient||Condition Treated||Highest Phase||Company|
|OBP801||spiruchostatin A||Solid Tumor, Glaucoma||Phase I||Oncolys Biopharma Inc|
|OKI-179||--||Breast Cancer||Preclinical||OnKure Inc|
|Chromopeptide A||--||Prostate Cancer||Preclinical||Zhejiang Hisun Pharmaceutical Co Ltd|
Oncolys Biopharma is developing OBP801 (spiruchostatin A), a cyclic depsipeptide, for the treatment of various solid cancers and glaucoma. OBP801 acts by targeting histone deacetylase. In 2015, Oncolys Biopharma initiated a Phase Ia study of OBP801 in patients with advanced solid tumors (3). In addition, OBP801 is in preclinical development for glaucoma. In 2016, Oncolys BioPharma entered into a collaboration with Kyoto Prefectural University of Medicine to research the potential application of OBP801 for the prevention of post-surgery scarring in glaucoma patients (2).
OnKure Inc, a University of Colorado spinoff, is developing OKI-179 for the treatment of triple-negative breast cancer (2). OKI-179 is a derivative of largazole, a cyclic depsipeptide that was isolated from the marine cyanobacterium Symploca sp. (4). This drug candidate targets HDAC6. In 2018, OnKure raised USD 7 million Series A financing. The company plans to use the funds for the development of OKI-179 and other drug candidates in its pipeline (2).
Chromopeptide A is under development by Zhejiang Hisun Pharmaceutical for the treatment of prostate cancer. This drug candidate is a depsipeptide originally isolated from the marine sediment-derived bacterium Chromobacterium sp. Chromopeptide A targets HDAC1, HDAC2, HDAC3 and HDAC8 to stop uncontrolled proliferation and differentiation of cancer cells. In preclinical trials, Zhejiang Hisun Pharmaceutical found that Chromopeptide A suppressed the growth and migration of prostate cancer in vitro and in vivo (2).
HDAC inhibitors are emerging as anti-cancer drugs and they may have potential beyond cancer. To support researchers and organizations who are studying histones and histone deacetylases, Bachem offers a selection of histone fragments, histone deacetylase substrates and histone building blocks. In addition, Bachem offers a comprehensive custom peptide synthesis service and the production of New Chemical Entities.
(1) A.K. Singh et al., Targeting histone deacetylases with natural and synthetic agents: An emerging anticancer strategy, Nutrients. 10(6), 731 (2018)
(2) GlobalData (2018)
(3) Medtrack (2018)
(4) K. Taori et al., Structure and activity of largazole, a potent antiproliferative agent from the Floridian marine cyanobacterium Symploca sp., J. Am. Chem. Soc. 130(6), 1806-1807 (2018)
What is your official job title at Bachem?
I am the Director of Production at Bachem UK.
How long have you been with Bachem? Where did you work before Bachem?
I have worked for Bachem for almost 15 years now. I joined the company as a Synthesis Chemist not long after completing my undergraduate studies. I became Synthesis Manager a few years later before assuming my current role in 2013.
What is your academic background/degrees or training?
I have a BSc in Forensic & Analytical Chemistry and then whilst working with Bachem, I completed my PhD in Investigative Medicine.
What do you like to do outside of work?
Spending time with family, friends and at the Liverpool Football Club.
What is your business motto?
When I was younger my father always told me “if a job is worth doing, then it is worth doing properly”. I still find the relevance in that statement every single day.
What do you like most about your job?
The variety. At Bachem UK we work on a vast number of different projects at any one time and I am fortunate enough to be involved in the majority of them. As a result, every day brings different challenges.
What is your preferred peptide?
I’d have to say Peptide YY as it formed the basis of my PhD studies. Even now, many years later I could probably still recount the amino acid sequence without even checking!
Thank you very much Iain.
Interesting news about peptides in basic research and pharmaceutical development:
Promising new therapy spares muscle loss in Duchenne muscular dystrophy-University at Buffalo
New research reveals a mitochondrial gene that protects against dementia and other diseases of aging-University of Southern California
New hurdle for developing immunotherapies-Science Daily
Cyclic peptides for cancer therapy and prognosis assessment-Medical Xpress